298060 — SCM LifeScience Co Balance Sheet
0.000.00%
- KR₩19bn
- KR₩25bn
- KR₩825m
Annual balance sheet for SCM LifeScience Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | ARS | ARS | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 34,171 | 18,890 | 6,916 | 4,496 | 920 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 123 | 125 | 67.6 | 139 | 173 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 36,086 | 20,312 | 10,040 | 13,260 | 1,996 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 11,544 | 11,117 | 10,650 | 10,254 | 20,450 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 76,292 | 54,045 | 33,020 | 25,404 | 23,170 |
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 3,259 | 8,709 | 4,562 | 1,148 | 5,741 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 13,213 | 9,432 | 8,509 | 4,930 | 8,991 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 63,079 | 44,613 | 24,511 | 20,474 | 14,179 |
Total Liabilities & Shareholders' Equity | 76,292 | 54,045 | 33,020 | 25,404 | 23,170 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |